Try our Advanced Search for more refined results

Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al

  1. October 19, 2021

    Shkreli Cites Rehab Too Late To Delay FTC Antitrust Trial

    A New York federal judge on Tuesday refused to delay the Federal Trade Commission's antitrust trial against Martin Shkreli, finding that the incarcerated former pharmaceutical executive tried too late to use his participation in a prison drug rehabilitation program to push the proceedings back from mid-December to May.

  2. October 18, 2021

    FTC Says Shkreli Has No Good Reason To Delay Antitrust Trial

    The Federal Trade Commission is fighting back against disgraced former pharmaceutical executive Martin Shkreli's bid to have his mid-December civil trial pushed back to May, telling a New York federal judge that it is simply the latest in a line of attempts to delay trial.

  3. October 14, 2021

    Shkreli Wants FTC's Monopolization Trial Pushed Back

    Disgraced former pharmaceutical executive Martin Shkreli wants his mid-December civil trial pushed back to May, telling the New York federal judge overseeing the bench trial that without a delay he will be facing a "Hobson's choice" that could leave him in jail an extra year.

  4. September 27, 2021

    Shkreli's Pharma Venture Loses Bid To Limit Profit Payback

    Incarcerated former pharmaceutical executive Martin Shkreli and Vyera Pharmaceuticals cannot put geographic limits on the profits they may have to cough up after spiking the price of a lifesaving drug, a New York federal judge has ruled.

  5. September 09, 2021

    Shkreli Antitrust Trial Slated For Mid-December

    Disgraced former pharmaceutical executive Martin Shkreli will face an in-person bench trial in mid-December in the Federal Trade Commission's case accusing him and the company he founded, Vyera Pharmaceuticals LLC, of monopolizing the market for a lifesaving drug.

  6. June 03, 2021

    FTC Can't Seek Restitution From Shkreli Until Congress Acts

    A New York federal judge permitted the Federal Trade Commission to withdraw its bid for financial restitution against disgraced pharmaceutical executive Martin Shkreli and his company, Vyera Pharmaceuticals LLC, on Wednesday given the U.S. Supreme Court's recent ruling that the agency lacks the power to recoup money from lawbreakers.

  7. June 01, 2021

    Shkreli Punished For Secret Phone But Can Deny Conspiracy

    A New York federal judge on Tuesday sanctioned disgraced pharmaceutical executive Martin Shkreli, after finding that the Federal Trade Commission demonstrated that Shkreli used a contraband phone to conduct business affairs while still incarcerated.

  8. May 21, 2021

    Shkreli, Vyera Rip FTC Sanction Bid Over Alleged Phone Wipe

    Disgraced pharmaceutical executive Martin Shkreli and his company Vyera Pharmaceuticals LLC on Friday urged a New York federal judge to reject the Federal Trade Commission's bid for sanctions against them, arguing the penalty over the alleged wiping of phones containing potential evidence is unwarranted and extreme.

  9. May 19, 2021

    FTC Wants Shkreli Sanctioned For Allegedly Wiping Phone

    The Federal Trade Commission has asked a New York federal judge to sanction Martin Shkreli for allegedly deleting text messages from a contraband prison phone that show he directed associates to continue blocking generic versions of the pricey anti-parasite drug that made him infamous.

  10. May 17, 2021

    Shkreli Cos.' Ability To Pay Penalties Irrelevant, FTC Says

    The Federal Trade Commission has asked a New York federal judge to exclude a proposed expert witness in its antitrust suit against incarcerated "pharma bro" Martin Shkreli and his companies, arguing that his planned testimony regarding the companies' ability to pay any financial penalty has no bearing on the case.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!